Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tipranavir.

Zelalem Temesgen1, Francesca Cainelli, Sandro Vento

  • 1Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota 55905, USA. temesgen.zelalem@mayo.edu

Drugs of Today (Barcelona, Spain : 1998)
|January 6, 2006
PubMed
Summary

Tipranavir, a new protease inhibitor, shows potent activity against drug-resistant HIV-1 and HIV-2. It offers a valuable new option for salvage therapy in treatment-experienced patients when boosted with ritonavir.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical education in low- and middle-income countries must be innovated without neglecting its foundational principles.

Frontiers in medicine·2026
Same author

Hepatitis D virus infection in sub-Saharan Africa: a scarcely studied, yet important issue.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Hepatitis C virus and HIV transmission: parenteral (including percutaneous) routes are still relevant and must receive due attention.

Frontiers in public health·2026
Same author

Overcoming structural barriers to tuberculosis treatment in Africa through digital technologies.

The Lancet. Microbe·2026
Same author

Research priorities for data science and artificial intelligence in global health: an international consensus exercise.

The Lancet. Global health·2026
Same author

HIV infection should no longer be detected at late stages in Italy.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026

Area of Science:

  • Pharmacology
  • Virology
  • Infectious Diseases

Background:

  • Human immunodeficiency virus (HIV) treatment relies on protease inhibitors.
  • Emergence of drug-resistant strains necessitates novel therapeutic agents.
  • Tipranavir represents a new class of protease inhibitors.

Purpose of the Study:

  • To evaluate the efficacy and safety of tipranavir in patients with treatment-experienced HIV.
  • To assess tipranavir's activity against protease inhibitor-resistant HIV isolates.
  • To determine the role of ritonavir in achieving therapeutic tipranavir concentrations.

Main Methods:

  • Randomized, phase III, open-label clinical trials.
  • Comparison with existing boosted protease inhibitors.
  • Evaluation of in vitro activity against HIV-1 and HIV-2, including resistant strains.

Main Results:

  • Tipranavir demonstrated superior efficacy compared to current boosted protease inhibitors in highly treatment-experienced patients.
  • Potent in vitro activity observed against multi-drug resistant HIV isolates.
  • Coadministration with ritonavir is necessary for achieving clinically relevant serum concentrations.

Conclusions:

  • Tipranavir is an effective new option for salvage antiretroviral therapy in patients with multiple protease inhibitor mutations.
  • Adverse effects include diarrhea, nausea, and vomiting.
  • Potential for elevations in cholesterol, triglycerides, and liver enzymes requires monitoring.

Related Experiment Videos